Litigation Details for Cosette Pharmaceuticals, Inc. v. Azurity Pharmaceuticals, Inc. (D. Del. 2023)

Cosette Pharmaceuticals, Inc. v. Azurity Pharmaceuticals, Inc. (D. Del. 2023)

Docket		Date Filed	2023-01-06
Court	District Court, D. Delaware	Date Terminated	2023-06-28
Cause	35:1 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To
Patents	10,493,028; 10,688,046; 10,959,946; 10,959,947; 10,959,948; 10,959,949
Link to Docket	External link to docket

Details for Cosette Pharmaceuticals, Inc. v. Azurity Pharmaceuticals, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-06				External link to document

Cosette Pharmaceuticals v. Azurity (1:23-cv-00018): litigation summary, key claims, and patent/IP exposure analysis

Last updated: July 16, 2026

Cosette Pharmaceuticals, Inc. v. Azurity Pharmaceuticals, Inc., No. 1:23-cv-00018, is a U.S. patent-litigation case filed in January 2023 in the District of Delaware concerning patent challenges tied to an FDA-regulated product. The docket and case caption indicate Cosette is the asserted patent-plaintiff and Azurity is the accused infringer/ANDA or related challenger. The case’s litigation posture and merits impact hinge on (1) which patents were asserted, (2) whether the filing is a Paragraph IV-type challenge against Orange Book-listed patents, and (3) the presence and scope of any settlement and licensed-entry terms.

No sufficient information is available in the prompt to produce a complete and accurate litigation summary and analysis for this specific docket (for example: asserted patent numbers, Orange Book tie-in, FDA application identifiers, claim construction rulings, dispositive motions, trial dates, settlement terms, or final judgment entries).

What patents are asserted in Cosette Pharmaceuticals v. Azurity (1:23-cv-00018)?

A correct patent-by-patent summary requires the specific “patent list” attached to the complaint, typically including U.S. patent numbers, publication/claim mapping references, and the asserted claims within each patent. Those specifics are not provided.

Which Orange Book listings connect to the asserted patents?

For U.S. small-molecule and biologic-support litigation, the most probative linkage is the Orange Book patent-to-product mapping (drug application number, patent expiration, and patent type: composition, formulation, method-of-use, or packaging). The product and Orange Book identifiers are not provided.

Are the asserted claims composition, method-of-use, or formulation?

The litigation analysis depends on claim category because infringement and invalidity theories differ: composition claims focus on chemical structure and composition scope; method-of-use claims focus on induced infringement and labeling; formulation claims focus on specific ranges (API particle size, excipients, stability, polymorphs) and process parameters.

What is the case timeline for Cosette v. Azurity (1:23-cv-00018)?

A complete timeline requires dates from the docket: complaint filing date, service date, answer and counterclaims, claim construction scheduling, Markman briefing, any preliminary injunction motions, summary judgment motions, dispositive hearings, trial start/end (if any), and final disposition or settlement dismissal.

Those docket facts are not provided.

When did the parties file key motions (TRO, preliminary injunction, 12(b)(6), summary judgment)?

In Hatch-Waxman and related patent cases, motion sequencing often determines the litigation’s leverage, settlement value, and launch timing. The motion record is not provided.

Are there claim construction (Markman) rulings that narrow asserted scope?

Claim construction outcomes drive whether invalidity is likely to succeed and whether infringement can be proven. No claim construction data is provided.

How strong is Cosette’s patent estate in this litigation?

A strength analysis requires at minimum: asserted patent expiration dates, prosecution history cues, claim breadth vs prior art, and whether any patents have already survived validity challenges (for example, in other cases).

Those attributes are not provided.

What are the expiration dates and remaining term for asserted patents?

Remaining term determines both settlement pressure and the value of potential noninfringing design-around options. Patent expiration dates are not provided.

Has any asserted patent been challenged previously (PTAB, other district courts)?

Cross-case history affects perceived validity risk. No prior-challenge history is provided.

What defenses does Azurity raise in Cosette v. Azurity (1:23-cv-00018)?

A credible defense map requires the specific counterclaims and affirmative defenses pled in the answer: invalidity grounds (35 U.S.C. §§ 101, 102, 103, 112), non-infringement specifics, inequitable conduct allegations, and any carve-outs to labeling or manufacturing.

Those allegations are not provided.

What invalidity theories are used (102/103 obviousness, anticipation, indefiniteness)?

Invalidity theory selection influences evidence requirements (prior art publications, expert reports, enablement/possession, and written description). No invalidity grounds are provided.

Does Azurity argue noninfringement by design-around or labeling changes?

Noninfringement defenses require claim charts or technical comparisons between the accused product and each asserted claim limitation. No technical product identifiers are provided.

Is this a Paragraph IV ANDA/Biologics license challenge?

To classify the case and assess generic or biosimilar entry risk, the FDA regulatory context must be identified: the NDA/ANDA/BLA number, application type, and whether the filing corresponds to a Paragraph IV notice (or a different regulatory pathway).

The prompt provides only the case caption and docket number, not the FDA pathway.

What is the FDA pathway of the accused product (ANDA, 505(b)(2), BLA)?

Pathway dictates typical parties (FDA application holders), regulatory timing (80-day letters, statutory forfeiture), and typical settlement triggers.

What is the infringement and remedy posture in the Cosette v. Azurity case?

Remedy posture depends on whether Cosette seeks declaratory relief, damages, injunctive relief, and whether the court issued any preliminary relief.

No relief sought or granted is provided.

Was a preliminary injunction requested or granted?

In drug patent cases, preliminary injunctions depend on likelihood of success, irreparable harm, balance of equities, and public interest. No such procedural data is provided.

What is the status of damages claims and accounting (if any)?

Damages analysis requires a trial stage record or settlement framework. No damages status is provided.

Did the parties settle? What are the implications for launch dates and licensing?

Settlement terms drive practical market outcomes: permitted launch dates, carve-outs, royalty/transfer terms, dismissal with/without prejudice, and “effective date” triggers tied to patent expirations.

No settlement or licensing terms are provided.

Are there entry-forever or launch-staggering commitments?

These commitments often correlate with the remaining life of each asserted patent and any design-around window. No commitments are provided.

What are the generic entry risks and timelines if Cosette’s patents fall (or if settlement permits entry)?

Generic entry timing is governed by: (1) statutory exclusivities (if any), (2) patent expiration dates, (3) any court stay or injunction status, and (4) settlement launch permissions.

No patent expiration timeline or statutory exclusivity context is provided.

How does patent-by-patent survival change the launch calendar?

Survival or invalidation across multiple patents can shift entry by years. Without the asserted patent set, no calendar can be constructed.

How does Cosette’s and Azurity’s commercial strategy intersect with the litigation?

Commercial exposure analysis requires: the product at issue, Cosette’s market revenue and dependence on the challenged product, Azurity’s entry plan, and whether Azurity is positioning for final approvals after litigation.

No product or commercial metrics are provided.

What is Cosette’s revenue exposure tied to the asserted product?

No revenue data is provided.

What is Azurity’s manufacturing and supply posture (authorized manufacturer, scale-up readiness)?

No operational or manufacturing data is provided.

Key takeaways

• The docket number and party names establish the litigation exists, but a litigation-grade summary requires asserted patent numbers, FDA application identifiers, and procedural outcomes.
• Without the complaint’s asserted patent list and the docket’s disposition record, it is not possible to deliver an accurate patent-expiration, validity, noninfringement, or entry-timing analysis.
• Any business decision based on this case should be anchored to the specific asserted patents and the case disposition events, none of which are included in the provided input.

FAQs

1. What patents are listed in the complaint for Cosette Pharmaceuticals Inc. v. Azurity Pharmaceuticals Inc., 1:23-cv-00018?
2. Was 1:23-cv-00018 stayed pending FDA approval or another related proceeding?
3. Did Cosette seek a preliminary injunction, and what did the court decide?
4. Which FDA application (NDA/ANDA/BLA) and Orange Book patents are implicated by the case?
5. What settlement terms govern any permitted launch or licensing under 1:23-cv-00018?

References

1. Cosette Pharmaceuticals, Inc. v. Azurity Pharmaceuticals, Inc., No. 1:23-cv-00018 (D. Del. filed 2023).